Journal of Pharmaceutical Research and Integrated Medical Sciences (JPRIMS)
ISSN: 3049-1681, Vol. 02, Issue No. 02, 2025 (pp. 59-75)

REVIEW ARTICLE https://aktpublication.com/index.php/jprims/index

Nano Formulation Properties, Characterization, And Behaviour in Complex Biological Matrices: Challenges and Opportunities for Brain-Targeted Drug Delivery Applications

[1]*Hemkanti Patel, [2]Harshalata Kanwar

[1]Shri Rawatpura Sarkar Institute of Pharmacy Kumhari, Durg, Chhattisgarh, India

[2]KIPS, Shri Shankaracharya Professional University, Bhilai, Chhattisgarh, India, 491001

*Corresponding Author E-mail: hemkantipatel2050@gmail.com

Synthetic as well as cell-based nanocarriers have come into great consideration for treating neurodegenerative diseases as well as other cerebral conditions. How well the brain-targeting delivery of drugs happens using Nano formulations is hugely determined by the physicochemical parameters such as size, shape, hydrophobicity, elasticity, and charge/chemistry/morphology at the surface of the drug nanocarrier, which determines their mode of interaction with living systems. One of the key determinants of their in vivo behavior is the protein corona formation, which governs nanoparticle recognition, circulation, and biodistribution. It is important to understand the biological matrices and cell culture compositions involved in protein corona formation in order to design efficient nanomedicines. In addition, characterization of nanocarriers in complex biological environments poses specific challenges, and advanced analytical methods need to be developed and used. This review discusses the types and properties of brain-targeted nanocarriers, there in vivo interactions, and the characterization methods employed for them. We also discuss the strengths and weaknesses of existing analytical tools, the difficulties in applying these methods in a Good Manufacturing Practice (GMP) setting, and the promise of orthogonal complementary characterization methods. By overcoming these challenges, this review will offer the insights into how the translational value of nanomedicines in brain disorders can be improved.

Key Words:

Brain-Targeted Drug Delivery, Nanocarriers, Protein Corona, Blood-Brain Barrier (BBB), Physicochemical Properties, Nanoparticle Characterization, Biological Matrices.

Article History:

Received Jan 25,2025

Accepted Feb 16,2025

Published Feb 28 ,2025

1. INTRODUCTION

Nanomedicine is transforming the delivery of drugs, particularly for brain targeting, for which traditional therapies face extreme challenges with the blood-brain barrier. Therapeutic treatment for neurological

diseases such as Alzheimer's, Parkinson's, glioblastoma, and epilepsy are restricted by the BBB[1], an extreme physiological barrier that hinders most macromolecules, including drugs, from entering the brain. Nanocarriers like liposomes, polymeric nanoparticles, dendrimers, micelles, and exosomes facilitate controlled release of medication, bioavailability, and therapeutic index of neuroactive chemicals. In biological systems, the behavior of Nano formulations is highly dynamic and governed by physicochemical properties like particle size, surface charge, hydrophobicity, and chemical composition[2]. Nanocarriers also establish a protein corona with biological fluids, proteins, and immunological constituents upon entry into the body, changing their biological identity and affecting circulation, cellular uptake, and clearance. The success of nanomedicine design and brain-targeted therapy relies on such understanding of the interactions[3]. Biomedical matrices such as blood, cerebrospinal fluid, and brain tissue are heterogeneous, complicating the characterization of Nano formulation. Sophisticated analytical techniques are essential to characterize nanoparticles' protein corona, which influences their pharmacokinetics, biodistribution, and cell interactions. Behavior of nanoparticles in body fluids is analyzed by DLS, zeta potential, TEM, LC-MS, and SPR[4]. These techniques cannot characterize physiological conditions in real time. Scalability issues, regulatory approvals, and GMP make it challenging to translate laboratory-based Nano formulation techniques to the clinic.

1.1. Background Information and Context

Nanomedicine enhances precision, bioavailability, and targeted therapy, transforming drug delivery. This is crucial when treating neurological diseases, where the blood-brain barrier restricts conventional medication. The BBB shields the brain against harmful substances and restricts life-saving medicine delivery[5]. Liposomes, polymeric nanoparticles, dendrimers, micelles, and extracellular vesicles are good candidates for the above challenges. Because they can permeate across the BBB, escape immune elimination, and deliver drugs to the brain, they play a critical role in neurotherapeutics. Physical-chemical characteristics such as size, shape, charge on the surface, and chemical makeup influence their stability, biodistribution, and biological interaction with surrounding entities, thus impacting their success[6]. Nano formulation science is also hindered by the protein corona effect, which encapsulates nanoparticles with proteins from biological fluids and alters their properties. This dynamic interaction is challenging for nanoparticle characterization and necessitates the development of novel analytical techniques to address their performance in multicomponent biological matrices such as blood, cerebrospinal fluid, and brain tissues.

1.2. Objectives of the Review

- To investigate the effects of nanocarriers' physicochemical characteristics on drug delivery that targets the brain.
- To investigate how the protein corona affects the circulation, biodistribution, and BBB penetration of nanoparticles.
- To determine methods for improving brain-targeted nanomedicines' capacity for translation.

1.3. Importance of the Topic

Brain disorders, such as Alzheimer's disease, Parkinson's disease, glioblastoma, and stroke, are among the most difficult-to-treat clinical conditions because they have limited therapeutic options and inefficient existing drug delivery systems. The promise of Nano formulations is that they could revolutionize neurotherapeutics by allowing targeted drug delivery, minimizing systemic side effects, and enhancing patient outcomes[7].

Nevertheless, while promising, their clinical translation is hampered by a number of challenges. The lack of predictability of protein corona formation, inability to precisely describe nanoparticles in the biological matrix, and scaling-up challenges in the manufacturing process present major challenges[8]. Overcoming these challenges is paramount for the translational development of brain-targeted nanomedicine from bench science to practical clinical use. This review gives a critical analysis of Nano formulation characteristics, characterization approaches, and in vivo performance, presenting insights into breaking through existing bottlenecks and opening up new possibilities in brain-targeted drug delivery.

2. NANOFORMULATION PROPERTIES AND THEIR INFLUENCE ON IN VIVO BEHAVIOR

The effectiveness of nanocarriers for brain-targeted drug delivery relies on their interactions with the biological environment, which are determined by their physicochemical properties, protein corona formation, and other biological determinants[9]. Elucidating these characteristics is essential for the optimization of Nano formulations to achieve efficacious transport across the blood-brain barrier (BBB), avoid immune clearance, and improve therapeutic outcomes.

2.1. Physicochemical Properties of Nanocarriers

Physicochemical properties of nanocarriers are essential in determining how they will act in biological systems. These properties determine nanoparticle stability, circulation time, target efficiency, and interactions with the biological fluid and cellular constituents. The major physicochemical features that impact the performance of Nano formulation include:

- **Size:** Particle size is an essential factor determining if nanoparticles can pass through the BBB. Experiments indicate that nanoparticles between 10-200 nm demonstrate maximum transport through the barrier, with smaller nanoparticles (<10 nm) likely to be cleared by the kidneys rapidly and larger ones (>200 nm) likely to be engulfed by the RES. Particle size also affects the uptake at the cell level, with smaller particles potentially being taken up more efficiently by endocytosis, whereas larger particles tend to accumulate in the peripheral tissue.
- **Shape:** Morphology of the nanoparticles determines how they are circulated and distributed biodistribution-wise within the body[10]. Spherical nanoparticle particles in general have a longer blood half-life and greater cellular uptake, whereas rod or disk-shaped ones might have superior adhesion onto endothelial cells but reduced fluidity in circulation. Elongated particles, e.g., nanorods, have recorded greater BBB penetrability efficiency by some research findings, but they have complicated dynamics in clearance as well.

- **Hydrophobicity:** The hydrophobicity of nanocarrier surfaces influences their interaction with plasma proteins, impacting protein corona formation, immune recognition, and cellular uptake. Hydrophilic nanoparticles, e.g., PEG-coated nanoparticles, have increased circulation times and lower immune clearance, making them ideal for brain-targeted delivery. Highly hydrophobic particles, on the other hand, might show strong protein interactions and thus rapid clearance.
- **Elasticity:** The physical characteristics of nanocarriers, such as their stiffness or flexibility, affect their cellular internalization and circulation. Research indicates that soft nanoparticles (e.g., liposomes or polymeric micelles) have superior deformation abilities, which enables them to escape immune clearance and penetrate cellular membranes more effectively. Stiff particles, conversely, might resist deformation but have longer circulation durations[11].
- **Surface Charge and Chemistry:** Nanocarrier surface charge is a major determining factor for stability, immune recognition, and target ability. Positively charged nanoparticles tend to exhibit increased cellular uptake through electrostatic attraction of negatively charged cell membranes but at the cost of inducing cytotoxicity and immune activation. By contrast, neutral or slightly negatively charged nanoparticles possess longer circulation time and lower immune recognition. Surface modification with PEGylation or ligand functionalization has the additional benefit of improving the targeting efficiency through decreased opsonization and increased receptor-mediated uptake in brain tissue.

2.2. Protein Corona Formation and Its Impact on Brain-Targeted Nanocarriers

Once nanocarriers reach biological settings like blood or cerebrospinal fluid (CSF), they quickly adsorb a corona of proteins, thus forming what has come to be called the protein corona. The dynamic and continually changing adsorbed layer of proteins remodels the nanoparticle's native surface characteristics and, in a highly significant manner, affects its biodistribution, cell uptake, and immune recognition. The makeup of the protein corona will rely on the physicochemical character of the nanocarrier as well as the prevailing proteins within the biologic fluid.



Figure 1: Protein Corona Formation[12]

The development of a protein corona affects some key aspects of brain-targeted drug delivery, such as:

- **Cellular Recognition and Uptake:** The corona proteins on the surface of the nanoparticle dictate whether or not the nanocarrier is identified by particular receptors present on brain endothelial cells, which in turn affects endocytosis and transcytosis through the BBB. Depending on the enrichment of the corona with apolipoproteins (such as ApoE, ApoA-I), the particle can have enhanced brain uptake through

lipoprotein receptor-mediated transcytosis[13]. Conversely, a corona with an excess of opsonin's (like immunoglobulins and complement proteins) will result in efficient immune clearance.

- **Immune Evasion or Activation:** The corona's nature decides whether a nanoparticle is identified as foreign to the immune system. A stealth protein corona (albumin- or transferrin-enriched) could increase circulation time and allow for immune evasion, while an opsonized corona initiates phagocytic clearance by macrophages.
- **Biodistribution and Mechanisms of Clearance:** The protein corona content determines how nanoparticles cross biological barriers and distribute throughout the body. A corona of brain-targeting proteins could increase BBB permeability, while a plasma protein corona might target the nanoparticle to the liver and spleen for clearance.
- **Efficiency Targeting for Brain Drug Delivery:** Because the protein corona might cover up the nanoparticle's initial surface ligands[14], the efficiency of active targeting approaches may be decreased. Scientists are preparing methods to pre-coat the nanocarriers with special biomolecules for directing protein corona composition and improving brain-targeted delivery.

With the important role of the protein corona, biocompatible and stable nanocarriers with the ability to regulate corona composition are critical considerations for creating effective brain-targeted drug delivery systems.

2.3. Biological Factors Affecting Nano formulation Performance

The in vivo action of Nano formulations is also controlled by a number of biological factors, which affect their biodistribution, stability, and capability to enter the brain[15]. They are:

- **Blood-Brain Barrier Permeability:** The BBB is composed of tight junctions, astrocytes, and pericytes, which regulate the transport of substances to the brain strictly. Nano formulations must be designed to bypass or regulate BBB permeability either through passive diffusion (lipophilic small-sized nanoparticles) or active transport processes such as receptor-mediated transcytosis (RMT) or adsorptive-mediated transcytosis (AMT). Certain nanoparticles can temporarily open the BBB for drug delivery.
- **Enzymatic Degradation and Clearance Mechanisms:** Upon entering the bloodstream, nanocarriers are subject to enzymatic degradation, oxidative stress, and immune recognition, which may affect their stability[16]. Lipid nanoparticles and polymeric nanoparticles can be metabolically degraded by esterase's and lipases, reducing their therapeutic performance. The creation of enzyme-resistant coatings can increase nanocarrier stability and extend drug release.
- **Endocytosis and Transcytosis Pathways:** Nanoparticles are taken up by brain endothelial cells through multiple uptake mechanisms, such as clathrin-mediated endocytosis, caveolae-mediated transcytosis, and micropinocytosis. Knowledge of the preferred uptake pathway for various nanocarriers can maximize their design for increased BBB penetration efficiency.

Microenvironment Interactions in Neurological Diseases: The incidence of

neuroinflammation, oxidative stress, and altered metabolic activity in illnesses such as Alzheimer's and Parkinson's disease has the potential to influence nanocarrier targeting and distribution[17]. For instance, inflammatory cytokines have the potential to alter BBB permeability and thereby affect transport by nanoparticles. Additionally, illness-specific biomarkers (e.g., amyloid plaques, tau proteins, alpha-synuclein clumps) are potential targets for nanoparticle-directed therapies.

Through customization of nanocarrier characteristics for consideration of such biological variables, scientists are able to formulate optimal, brain-directed Nano products that are able to deliver drugs with efficient efficacy, minimize immune clearance, and optimize therapeutic impact against neurological disorders. The following table is an overview of how such Nano formulation characteristics affect in vivo behavior with focus on respective studies and the primary findings therein, as pertains to brain-targeted drug delivery.

Table 1: Reference Table

Reference	Nano Formulation Property	Impact on In Vivo Behavior	Study Focus	Findings
Sonali et al., 2016[18]	Size (10-200 nm)	Optimal BBB penetration; smaller particles cleared renally, larger ones by RES	Formulation of transferrin liposomes for brain-targeted cancer therapy	Docetaxel-loaded liposomes (~100 nm) exhibited enhanced brain accumulation and anticancer effects
Hong et al., 2018[19]	Shape (Spherical, Rod, Disk)	Spherical: longer circulation; Rods: better BBB penetration but complex clearance	PEGylated Nano-bacitracin A for meningitis treatment	Spherical nanoparticles showed prolonged systemic circulation and better BBB penetration than other shapes
Chatterjee et al., 2019[20]	Hydrophobicity (PEGylation vs. Hydrophobic)	Hydrophilic coatings improve circulation; hydrophobic surfaces enhance clearance	Intranasal Nano Emulsion for targeted drug delivery	PEGylated Nano Emulsions extended circulation time and reduced immune clearance
Hu & Hammarlund-Udenaes, 2020[21]	Elasticity (Soft vs. Rigid Nanoparticles)	Soft nanoparticles evade immune clearance; rigid ones have prolonged	Nano Delivery approaches for effective brain treatments	Liposomes (soft nanocarriers) exhibited better BBB penetration than rigid polymeric nanoparticles

		circulation		
Kulkarni et al., 2015[22]	Surface Charge (Positive, Neutral, Negative)	Positive charge increases uptake but induces toxicity; neutral charge improves circulation	Nose-to-brain delivery for Parkinson's therapy	Neutral or slightly negative charge improved biocompatibility and BBB penetration

3. CHARACTERIZATION TECHNIQUES FOR NANOCARRIERS IN COMPLEX BIOLOGICAL MATRICES

Characterization of nanocarriers in matrices of biological media is crucial in determining their stability, biodistribution, interaction with biomolecules, and therapeutic outcomes[23]. The behavior of biological fluids, including blood plasma and CSF, proves to be major challenges owing to protein corona formation, agglomeration of nanoparticles, and interference caused by biomolecules. Hence, several analytical, imaging, and spectroscopic techniques need to evaluate the physicochemical properties as well as biologic behavior of Nano formulations.

This section delves into principal analytical methods of characterizing Nano formulations, some of the problems with characterizing in biological environments, and deploying these techniques under a Good Manufacturing Practice (GMP) to facilitate clinical translation.

3.1. Analytical Techniques for Nano formulation Characterization

Various analytical methods are used to investigate the physicochemical characteristics of nanocarriers, their performance in biological matrices, and interaction with cellular components. The analytical methods are grouped under particle size analysis, imaging techniques, surface charge determination, and compositional analysis.

Particle Size and Stability Analysis

Dynamic Light Scattering (DLS): DLS is commonly employed to determine nanoparticle size distribution, polydispersity index (PDI), and stability in biological fluids[24]. The method relies on the light scattering by suspended particles, where smaller nanoparticles show quicker Brownian motion. DLS gives real-time data of nanocarrier size and aggregation behavior, which are essential for assessing stability under physiological conditions. It has some limitations in characterizing polydisperse or highly heterogeneous samples.



Figure 2: Dynamic Light Scattering (DLS)[25]

Nanoparticle Tracking Analysis (NTA): NTA measures the concentration and size of nanoparticles by monitoring their transport under a laser beam. Compared to DLS, NTA gives single particle size distribution and is thus

ideal for complex biological matrices where more than one nanoparticle population might be present.

- **High-Resolution Imaging Techniques**

Transmission Electron Microscopy (TEM): TEM provides high-resolution images of nanoparticles, allowing one to observe their size, shape, surface morphology, and aggregation in high detail. It is particularly beneficial for nanoscale analysis of liposomes, polymeric nanoparticles, and inorganic nanocarriers. The processing of TEM samples, however, can alter the nanoparticles' original structure, and careful optimization may be required.



Figure 3: Transmission Electron Microscopy (TEM)[26]

Scanning Electron Microscopy (SEM): As supplementary to TEM in structural characterization, SEM offers details regarding surface topography and topological information regarding nanoparticles. As a prerequisite despite conductive preparation being required, it is beneficial in determining coatings on the surface, roughness, and material integrity.

- **Surface Charge and Stability Analysis**

Zeta Potential Analysis: The surface charge and colloidal stability of nanoparticles in biological fluids are indicated by their zeta potential. While a low zeta potential can cause the agglomeration of nanoparticles, high absolute zeta potential (±30 mV or greater) indicates strong particle-to-particle repulsion, which avoids aggregation. Prediction of in vivo stability, cell interaction, and immunological recognition depend on this property.



Figure 4: Zeta Potential Analysis[27]

- **Compositional and Molecular Analysis**

Mass Spectrometry (MS) and Chromatographic Techniques: Chromatography and mass spectrometry, including Liquid Chromatography-Mass Spectrometry (LC-MS) and Gas Chromatography-Mass Spectrometry (GC-MS), are employed for the analysis of protein corona composition and for the identification of surface-adsorbed biomolecules. The methods identify the ways in which the biological milieu alters nanoparticle properties.

Fourier Transform Infrared Spectroscopy (FTIR): FTIR identifies chemical functional groups on surfaces of nanocarriers, enabling researchers to investigate surface modification,

ligand conjugation, and biofunctionalization[28]. These methods together offer a complete profile of nanocarriers, allowing for accurate optimization for applications in brain-targeted drug delivery.

3.2. Challenges in Characterization within Complex Biological Matrices

In spite of the presence of sophisticated characterization methods, some challenges remain while characterizing nanocarriers in a biological environment of complexity:

- **Dynamic Composition of Protein Corona:** The protein corona on the surface of nanoparticles dynamically changes over time and modifies the identity and function of the nanocarrier. As proteins adsorb at variable rates, it is difficult to characterize them in real-time. Standardized approaches for tracking the evolution of protein corona are still being developed[29].
- **Effect of Biological Medium on Stability of Nanocarriers:** Physicochemical characteristics of nanoparticles can be altered upon interaction with biological fluids because of pH changes, ionic strength fluctuations, and enzyme degradation. Stabilizing nanoparticles while maintaining therapeutic activity is a major challenge.
- **Biomolecule Interference Impacting Analytical Precision:** Proteins, lipids, and ions in blood, plasma, and cerebrospinal fluid interfere with nanoparticle characterization. For example, protein aggregation can bias DLS measurements[30], and spectroscopic methods can be plagued by background noise from biological molecules.
- **Insufficient Standardized Protocols for Large-Scale Characterization:** While different characterization methods are available at the research scale, validated and standardized protocols for commercial-scale pharmaceutical manufacturing are not present. It becomes challenging to confirm batch-to-batch reproducibility and regulatory acceptance.

Solving these issues involves the creation of interdisciplinary characterization platforms that integrate multiple supporting techniques for an overall understanding of Nano formulation phenomena within biological systems.

3.3. Implementation in a GMP Environment

In order for Nano formulations to move from laboratory studies to the clinic, characterization would need to comply with Good Manufacturing Practice (GMP) regulations laid down by drug regulatory authorities like the FDA (Food and Drug Administration, USA) and EMA (European Medicines Agency)[31]. Applying characterization methods in a GMP setting entails a number of important considerations:

- **Ensuring Reproducibility and Batch Consistency:** GMP guidelines demand very high reproducibility and negligible batch-to-batch variation in nanoparticle manufacturing. Sophisticated high-throughput analytical techniques and automated characterization platforms are crucial to ensuring consistency during large-scale manufacturing.
- **Compliance with Safety and Efficacy Regulations:** Regulatory bodies require rigorous quality control tests for nanomedicines, such as stability testing, biocompatibility assays, and long-term toxicity analysis. Methods like DLS, TEM, and zeta potential measurement need to be incorporated into quality control protocols.
- **Industrial Production Scalability of Analytical Methods:** Numerous characterization procedures like TEM and mass spectrometry are intensive in labor and trained staff. Industrial adoption relies

heavily on creating scalable automated characterization systems.

4. DISCUSSION

4.1. Interpretation and Analysis of Findings

Findings of the current study point out the contribution of biological interactions, drug transport efficacy, and Nano formulation characteristics in brain-targeted delivery. Physicochemical attributes of nanocarriers, such as size, shape, surface charge, and hydrophobicity, significantly contribute to determining stability of nanocarriers, cellular uptake, clearance processes, and biodistribution. One of the major issues in drug delivery using Nano formulation is the formation of a protein corona[32], an adsorbed layer of proteins, which changes nanoparticle properties within the biological context. The corona may modulate immune system interactions, biodistribution profiles, and cellular recognition, better or worse to drug delivery efficacy.

These protein interactions play a crucial role in the ability of nanocarriers to target drugs across the blood-brain barrier (BBB). Nanoparticles are intended to develop a protein corona that reduces immunological recognition and enables rapid clearance with maximal brain targeting[33]. But it is a challenging job to get reproducible and predictable outcomes due to the highly dynamic and patient-dependent nature of the protein corona composition. In addition, the functional surface ligands of nanocarriers may be hidden by the protein corona, which would reduce their receptor-mediated transport through the blood-brain barrier. To achieve the best therapeutic performance, optimization of Nano formulations needs to consider such interactions.

The clinical application of nanocarriers is further complicated by their characterization in complex biological matrices. Analytical techniques such as mass spectrometry, transmission electron microscopy (TEM), and dynamic light scattering (DLS) have provided data regarding the size, charge, and surface chemistry of nanoparticles. Biological milieus are a further complication in the form of protein corona composition variation, rapid nanoparticle activity variation, and biomolecule interference[34]. It is challenging to obtain reproducible, consistent data regarding Nano-bio interactions due to these problems. In addition, compliance with Good Manufacturing Practice (GMP) regulations—e.g., batch-to-batch consistency, reproducibility, and regulatory compliance—needs to be maintained when scaling up Nano formulations to commercial production scale. For nanomedicine to be beneficial in clinic applications, a number of issues need to be addressed.

4.2. Implications and Significance

Implications of Protein Corona Formation:

Formation of protein corona plays a central role in controlling the pharmacokinetics and biodistribution of nanocarriers. Once exposed to blood plasma, proteins on the surface rapidly adsorb on their surface, modifying their stability, targeting function, and pathway of clearance. This may lead to reduced bioavailability of drugs through opsonization, during which nanoparticles become recognized as foreign and are taken out of the body by the mononuclear phagocyte system (MPS). Protein adsorption has further potential to destroy ligand-receptor bonds and suppress nanocarriers from targeting the brain tissues[35]. The other significant effect of protein corona formation is on the activation of the immune system. If the corona is largely made up of immunogenic proteins, the nanoparticles will

be able to induce inflammatory reactions, which results in systemic toxicity and decreased therapeutic efficacy. On the other hand, a well-designed protein corona can promote nanoparticle stability, extended circulation time, and receptor-mediated transport across the BBB[36]. It is therefore essential to determine the dynamics and structure of protein corona formation in order to develop Nano formulations that deliver the drug to a maximum extent and minimize side effects. By changing the surface chemistry of nanocarriers—e.g., through PEGylation or biomimetic surface engineering—researchers can prepare nanoparticles with controlled protein adsorption and improved pharmacokinetic profiles.

Strategies to Overcome Characterization Challenges:

Characterizing Nano formulations in intricate biological matrices is the most challenging aspect of nanomedicine research. The dynamic character of biological environments and the presence of proteins that interact with nanoparticles complicate measurement. Sophisticated imaging and spectroscopic methods for real-time Nano-bio interaction characterization can bypass this challenge[37]. Cryo-TEM photographs nanoparticles at high resolution in near-native conditions, enabling researchers to study biological conditions and structure modifications. The protein corona composition and nanoparticle surface modifications can be determined molecularly by Raman and FTIR.

Integrating analytical methods is another significant Nano formulation characterization option. Since no single technique can fully characterize Nano formulations in biological matrices, integrating DLS for hydrodynamic size, zeta potential for surface charge, nanoparticle tracking analysis (NTA) for particle size distribution, and proteomics-based mass spectrometry for protein corona analysis can help better understand nanoparticle behavior[38]. This multimodal approach helps scientists quantify nanocarrier-biological interaction and forecast in vivo performance.

Standardizing characterization processes helps with reproducibility and regulatory approval. Due to the lack of standardized Nano formulation characterization guidelines, experimental results have varied. Standardized methods would improve data comparability, regulatory evaluation of nanomedicine safety and efficacy, and clinical translation. To correctly convert research results to therapeutic applications, these processes must have clear nanoparticle manufacturing, protein corona analysis, and in vivo behavior testing methods.

4.3. Future Research Directions in Brain-Targeted Nanomedicine

1) Nanomedicine Personalization

Tailor-made therapy in brain-directed nanomedicine is an exciting prospective line. Nanocarriers have different interactions with physiological barriers, immunosurveillance, and disease-targeting microenvironments in every patient. Genotype- and phenotype-tailored nanocarriers according to genetic, proteomic, and metabolic markers might enhance medicine delivery and efficacy[39]. AI and machine learning can optimize Nano formulation designs, forecast patient responses, and tailor treatment of neurologic disorders such as Alzheimer's, Parkinson's, and glioblastomas. Personalized nanomedicine can enhance the efficacy of treatment and minimize adverse effects through big data and predictive modeling.

2) Stimulus-Responsive Smart Nanocarriers

Stimuli-responsive smart nanocarriers are yet another leading area of research. These smart

nanocarriers release the drugs based on physiological stimuli such as pH, enzyme activity, magnetic field, or ultrasound. pH-sensitive nanoparticles can release drugs in low pH tumor microenvironments and enhance targeting of targeted drugs with enhanced systemic toxicity. Spatial and temporal therapeutic control through remote-controlled drug release by magnetic and ultrasound-stimulated nanocarriers is feasible. Redox-sensitive nanoparticles, triggered by oxidative stress associated with neurodegenerative diseases, represent another fascinating targeted drug delivery strategy. Such smart nanocarriers have the potential to revolutionize brain-targeted drug delivery by enhancing therapeutic selectivity and reducing off-target toxicity.

3) Nano-Bio Interaction Predictive Modeling using Machine Learning

Machine learning (ML) and AI in nanomedicine studies hold great promise for drug delivery improvements[40]. ML algorithms may discover trends in huge Nano formulation experiment datasets to enhance nanoparticle shape for targeting efficiency. Deep learning models can predict Nano-bio interactions to increase BBB penetration and reduce immunological stimulation by optimizing nanoparticle properties. AI-based systems can automate data analysis from diverse methodologies and reduce experimental mistakes in Nano formulation characterization. Machine learning in nanomedicine research can speed up the design of next-generation nanocarriers, improving brain-targeted therapy efficacy.

5. CONCLUSION

5.1. Summary of Insights

This research emphasizes the significant function of Nano formulations in brain-targeted drug delivery for neurological disorder treatment. The physicochemical characteristics of nanocarriers, such as size, shape, surface charge, and hydrophobicity, have a profound effect on their interaction with biological matrices, especially on crossing the blood-brain barrier (BBB). One of the main issues in Nano formulation design is the development of a protein corona, which changes nanoparticle stability, biodistribution, and targeting efficacy. While the protein corona can promote or hinder drug delivery, one must understand its composition and dynamics to optimize nanocarrier performance.

The second serious challenge is the characterization of nanocarriers within complex biological environments. Present analytical tools, such as dynamic light scattering (DLS), transmission electron microscopy (TEM), and mass spectrometry, provide useful information regarding nanoparticle size, charge, and surface properties. The dynamic nature of biological interactions brings in the element of heterogeneity, making characterization challenging. Resolving these challenges requires the convergence of multiple analytical techniques, advanced imaging modalities, and the development of standardized protocols for reproducibility and clinical translation.

5.2. Importance of the Review

Nano formulating features in biological environments are pertinent to brain-targeting delivery, as is the case in this review. Due to BBB restriction, neurologic illnesses like Alzheimer's, Parkinson's, and glioblastomas are difficult to manage. Targeted drug delivery, reduction of systemic toxicity, and improvement in therapeutic efficacy are among the opportunities of nanomedicine. Therapeutic performance relies on overcoming inherent protein corona formation, immune recognition, and in vivo stability limitations. Rational

nanocarrier design optimization for drug delivery requires appropriate characterization of the biological system. This review highlights the requirement of transdisciplinary brain-targeted nanomedicine research. Biomolecular sciences, nanotechnology, and computational modeling have the capability to uncover Nano-bio interactions and allow more efficient and customized delivery of medicine. Researchers are able to accelerate the development of nanomedicine for neurological issues by overcoming Nano formulation design and characterization limitations.

5.3. Recommendations and Future Directions

To further improve the clinical relevance of Nano formulations for brain-targeted drug delivery, the following suggestions should be considered:

- **Increase knowledge on protein corona dynamics:** Future studies should be aimed at the composition and development of the protein corona in various biological environments to maximize nanoparticle stability and targeting efficacy.
- **Improve surface engineering techniques:** Techniques like PEGylation, biomimetic coatings, and ligand modifications need to be investigated to reduce immune recognition and enhance circulation time of nanoparticles.
- **Advance characterization methods:** High-resolution imaging (e.g., cryo-TEM, super-resolution microscopy), real-time tracking, and multi-omics approaches need to be integrated to obtain a deeper understanding of Nano-bio interactions.
- **Standardize protocols for characterization:** Regulatory agencies must have clear instructions for evaluating the characteristics of Nano formulation to ensure reproducibility and uniformity in clinical applications.
- **Implement customized nanomedicine approaches:** Patient-specific Nano formulation designs and AI-based predictive models should be explored to achieve the best treatment outcomes by individual biological profiles.
- **Improve stimuli-responsive nanocarriers:** Smart nanocarriers that release drugs in a controlled fashion by responding to physiological stimuli (e.g., temperature, enzymes, or pH) must be engineered with the goal of enhancing accuracy and reducing systemic side effects.
- **Encourage multidisciplinary collaboration:** Interdisciplinary cooperation among nanotechnology specialists, drug scientists, clinicians, and regulatory agencies is required to drive the development of brain-targeted nanomedicine and address existing limitations.

By following these approaches, the discipline of nanomedicine can speed up the design of efficient, safe, and manufacturable brain-targeted drug delivery systems, leading to better therapeutic outcomes for neurological diseases.

REFERENCES

1. Liu, Y., & Lu, W. (2012). Recent advances in brain tumor-targeted nano-drug delivery systems. *Expert opinion on drug delivery*, *9*(6), 671-686.
2. Khan, A. R., Yang, X., Fu, M., & Zhai, G. (2018). Recent progress of drug nanoformulations targeting to

brain. *Journal of Controlled Release*, *291*, 37-64.

3. Rawal, S. U., Patel, B. M., & Patel, M. M. (2022). New drug delivery systems developed for brain targeting. *Drugs*, *82*(7), 749-792.
4. Jampílek, J., & Král'ová, K. (2019). Natural biopolymeric nanoformulations for brain drug delivery. In *Nanocarriers for Brain Targeting* (pp. 131-204). Apple Academic Press.
5. Alexander, A., Agrawal, M., Uddin, A., Siddique, S., Shehata, A. M., Shaker, M. A., ... & Shaker, M. A. (2019). Recent expansions of novel strategies towards the drug targeting into the brain. *International journal of nanomedicine*, 5895-5909.
6. Kumar, L. A., Pattnaik, G., Satapathy, B. S., Swapna, S., & Mohanty, D. (2021). Targeting to brain tumor: Nanocarrier-based drug delivery platforms, opportunities, and challenges. *Journal of Pharmacy and Bioallied Sciences*, *13*(2), 172-177.
7. O Elzoghby, A., M Abd-Elwakil, M., Abd-Elsalam, K., T Elsayed, M., Hashem, Y., & Mohamed, O. (2016). Natural polymeric nanoparticles for brain-targeting: implications on drug and gene delivery. *Current pharmaceutical design*, *22*(22), 3305-3323.
8. Jampílek, J., & Králová, K. (2019). Nanotechnology-Based Formulations for Drug Targeting to the Central Nervous System. In *Nanoparticulate drug delivery systems* (pp. 151-220). Apple Academic Press.
9. Nagpal, K., Singh, S. K., & Mishra, D. N. (2013). Drug targeting to brain: a systematic approach to study the factors, parameters and approaches for prediction of permeability of drugs across BBB. *Expert opinion on drug delivery*, *10*(7), 927-955.
10. Ravuluri, J. A., Rao, V., Kumar, G., Manandhar, S., Cheruku, S. P., Bisht, P., ... & Kumar, N. (2023). Brain-targeted nano-architectures for efficient drug delivery and sensitization in glioblastoma. *Current Pharmaceutical Design*, *29*(22), 1775-1790.
11. Anwarkhan, S., Koilpillai, J., & Narayanasamy, D. (2024). Utilizing multifaceted approaches to target drug delivery in the brain: from nanoparticles to biological therapies. *Cureus*, *16*(9).
12. Jawad, M., Shafique, U., ud Din, F., Butt, A., Khan, S., Khan, G. M., ... & Almerai, K. S. (2024). Nose to brain delivery of escitalopram-loaded nano-structured lipid carriers thermosensitive gel: Formulation, physiochemical, pharmacokinetic and pharmacodynamics evaluation. *Journal of Drug Delivery Science and Technology*, *97*, 105800.
13. Wang, L., Shi, Y., Jiang, J., Li, C., Zhang, H., Zhang, X., ... & Feng, L. (2022). Micro-nanocarriers based drug delivery technology for blood-brain barrier crossing and brain tumor targeting therapy. *Small*, *18*(45), 2203678.
14. Zeeshan, M., Mukhtar, M., Ain, Q. U., Khan, S., & Ali, H. (2019). Nanopharmaceuticals: A boon to the brain-targeted drug delivery.

In *Pharmaceutical Formulation Design-Recent Practices* (pp. 1-15). IntechOpen.

15. Yousfan, A., Al Rahwanji, M. J., Hanano, A., & Al-Obaidi, H. (2023). A comprehensive study on nanoparticle drug delivery to the brain: application of machine learning techniques. *Molecular Pharmaceutics*, *21*(1), 333-345.

16. Alshawwa, S. Z., Kassem, A. A., Farid, R. M., Mostafa, S. K., & Labib, G. S. (2022). Nanocarrier drug delivery systems: characterization, limitations, future perspectives and implementation of artificial intelligence. *Pharmaceutics*, *14*(4), 883.

17. Surekha, R., & Sumathi, T. (2016). An efficient encapsulation of thymoquinone using solid lipid nanoparticle for brain targeted drug delivery: physicochemical characterization, pharmacokinetics and bio-distribution studies. *Int. J. Pharm. Clin. Res*, *8*(12), 1616-1624.

18. Sonali, Singh, R. P., Singh, N., Sharma, G., Vijayakumar, M. R., Koch, B., ... & Muthu, M. S. (2016). Transferrin liposomes of docetaxel for brain-targeted cancer applications: formulation and brain theranostics. *Drug delivery*, *23*(4), 1261-1271.

19. Hong, W., Zhang, Z., Liu, L., Zhao, Y., Zhang, D., & Liu, M. (2018). Brain-targeted delivery of PEGylated nano-bacitracin A against Penicillin-sensitive and-resistant Pneumococcal meningitis: Formulated with RVG29 and Pluronic® P85 unimers. *Drug delivery*, *25*(1), 1886-1897.

20. Chatterjee, B., Gorain, B., Mohananaidu, K., Sengupta, P., Mandal, U. K., & Choudhury, H. (2019). Targeted drug delivery to the brain via intranasal nanoemulsion: Available proof of concept and existing challenges. *International journal of pharmaceutics*, *565*, 258-268.

21. Hu, Y., & Hammarlund-Udenaes, M. (2020). Perspectives on nanodelivery to the brain: prerequisites for successful brain treatment. *Molecular Pharmaceutics*, *17*(11), 4029-4039.

22. Kulkarni, A. D., Vanjari, Y. H., Sancheti, K. H., Belgamwar, V. S., Surana, S. J., & Pardeshi, C. V. (2015). Nanotechnology-mediated nose to brain drug delivery for Parkinson's disease: a mini review. *Journal of drug targeting*, *23*(9), 775-788.

23. Elnaggar, Y. S., Etman, S. M., Abdelmonsif, D. A., & Abdallah, O. Y. (2015). Intranasal piperine-loaded chitosan nanoparticles as brain-targeted therapy in Alzheimer's disease: optimization, biological efficacy, and potential toxicity. *Journal of pharmaceutical sciences*, *104*(10), 3544-3556.

24. Yusuf, M., Khan, M., Alrobaian, M. M., Alghamdi, S. A., Warsi, M. H., Sultana, S., & Khan, R. A. (2021). Brain targeted Polysorbate-80 coated PLGA thymoquinone nanoparticles for the treatment of Alzheimer's disease, with biomechanistic insights. *Journal of Drug Delivery Science and Technology*, *61*, 102214.

25. Saeedi, M., Morteza-Semnani, K., Siahposht-Khachaki, A., Akbari, J., Valizadeh, M., Sanaee, A., ... & Rahimnia, S. M. (2023). Passive targeted drug delivery of venlafaxine hcl to the brain by modified chitosan nanoparticles: Characterization, cellular safety assessment, and in vivo evaluation. *Journal of Pharmaceutical Innovation*, *18*(3), 1441-1453.

26. Yan, X., & Chen, Q. (2024). Polyamidoamine Dendrimers: Brain-Targeted Drug Delivery Systems in Glioma Therapy. *Polymers*, *16*(14), 2022.

27. Yergök, R. A., Derman, S., Alakbarli, J., & Eskhıta, A. S. (2024). Brain-Targeted Nano-Drug Delivery for the Treatment of Parkinson's Disease. *Current Research in Health Sciences*, *1*(2), 77-92.

28. Yu, Y., Li, S., Kong, L., Du, Y., Liu, Y., Zang, J., ... & Li, X. (2024). Development of a brain-targeted nano drug delivery system to enhance the treatment of neurodegenerative effects of resveratrol. *Journal of Liposome Research*, *34*(3), 435-451.

29. Lowe, T. L., Agrahari, V., Kannan, R. M., & Kannan, S. (2019). Nanotechnology enabled regenerative medicine for neurological disorders. *Advanced drug delivery reviews*, *148*, 1.

30. Verma, S. K., Arora, I., Javed, K., Akhtar, M., & Samim, M. (2016). Enhancement in the neuroprotective power of riluzole against cerebral ischemia using a brain targeted drug delivery vehicle. *ACS Applied Materials & Interfaces*, *8*(30), 19716-19723.

31. Kozlovskaya, L., & Stepensky, D. (2013). Quantitative analysis of the brain-targeted delivery of drugs and model compounds using nano-delivery systems. *Journal of Controlled Release*, *171*(1), 17-23.

32. Sonkar, R., Jha, A., Viswanadh, M. K., Burande, A. S., Pawde, D. M., Patel, K. K., ... & Muthu, M. S. (2021). Gold liposomes for brain-targeted drug delivery: Formulation and brain distribution kinetics. *Materials Science and Engineering: C*, *120*, 111652.

33. Pires, P. C., & Santos, A. O. (2018). Nanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies. *Journal of controlled release*, *270*, 89-100.

34. Huang, D., Wang, Q., Cao, Y., Yang, H., Li, M., Wu, F., ... & Wang, Q. (2023). Multiscale NIR-II imaging-guided brain-targeted drug delivery using Engineered Cell membrane Nanoformulation for Alzheimer's Disease Therapy. *ACS nano*, *17*(5), 5033-5046.

35. Sivadasu, P., Gowda, D. V., Subramani, N. K., Malgur, B., Vishweshwaraiah, S. S., & Hatna, S. (2020). Direct brain targeted nanostructured lipid carriers for sustained release of schizophrenic drug: Formulation, characterization and pharmacokinetic studies. *brain*, *9*(12), 10-5530.

36. Girotra, P., Thakur, A., Kumar, A., & Singh, S. K. (2017). Identification of multi-targeted anti-migraine potential of nystatin and development of its brain

targeted chitosan nanoformulation. *International Journal of Biological Macromolecules*, *96*, 687-696.

37. C Dinda, S., & Pattnaik, G. (2013). Nanobiotechnology-based drug delivery in brain targeting. *Current Pharmaceutical Biotechnology*, *14*(15), 1264-1274.
38. Wei, X., Chen, X., Ying, M., & Lu, W. (2014). Brain tumor-targeted drug delivery strategies. *Acta pharmaceutica sinica B*, *4*(3), 193-201.
39. Mittal, D., Md, S., Hasan, Q., Fazil, M., Ali, A., Baboota, S., & Ali, J. (2016). Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route. *Drug delivery*, *23*(1), 130-139.
40. Ravichandran, V., Lee, M., Nguyen Cao, T. G., & Shim, M. S. (2021). Polysorbate-based drug formulateons for brain-targeted drug delivery and anticancer therapy. *Applied Sciences*, *11*(19), 9336.